By lBenedikt Fischer,  Didier Jutras-Aswad, Bernard Le Foll, Daniel T. Myra

Highlights

•

The province of British Columbia (Canada) temporarily implemented a decriminalization initiative for personal drug possession/use (2023–2024) in contexts of a toxic drug death crisis.

1. •

   The decriminalization initiative was a priori promoted as a “tool to end the overdose crisis” and widely expected to reduce adverse health outcomes from toxic drug use.

2. •

   Emerging evaluation data indicate that the drug decriminalization initiative was not associated with population-level changes in drug use-related mortality (e.g., overdose deaths) or morbidity (e.g., hospitalizations).

3. •

   Drug use decriminalization remains an essential step to align prohibition-based drug policy frameworks with public health and human rights principles, but must be approached realistically and designed sensibly.

4. •

   To tangibly address toxic drug use-related harms, expanded measures are required that are effectively capable of preventing and reducing PWUDs’ exposure to and use of toxic drugs
   International Journal of Drug Policy

Volume 150, April 2026, 105181

By Paul J. Larkin

The raw, agricultural form of cannabis is not capable of being approved for use by the Food and Drug Administration (FDA)—regardless of whether Congress or the U.S. Attorney General reschedules it downward from Schedule I. Rescheduling cannabis would not allow the drug to be distributed under federal law unless the FDA finds that it is a safe, effective, and uniform drug. The FDA could not do so under existing law, and the Attorney General cannot waive the Food, Drug, and Cosmetic Act’s requirements. Congress could do so by statute—but any such law would put at risk the health of users and nonusers in order to satisfy the desires of a minority for a transient high.

Washington, DC: The Heritage Foundation, 2023. 57p.